View Older Stories View More Recent Stories
-
Citi Reiterates Buy Rating on Boston Scientific (BSX)
-
Deutsche Bank Upgrades Boston Scientific (BSX) to Buy
-
Truist Securities Reiterates Buy Rating on Boston Scientific (BSX) Following Bolt Medical Acquisition
-
BTIG Reiterates Buy Rating on Boston Scientific (BSX) following Bolt Medical deal
-
Piper Sandler Reiterates Overweight Rating on Boston Scientific (BSX): 'We Expect the Stock Will Grind Higher'
-
Boston Scientific (BSX) to Acquire Bolt Medical
-
Boston Scientific (BSX) PT Raised to $101 at BTIG
-
Insulet Corporation (PODD) PT Raised to $300 at BTIG
-
Truist Securities Names Boston Scientific (BSX) as 'Favorite 2025 LGCP Pick'
-
Medical Technology and Devices: Piper Sandler Shares 'Quick Thoughts on HC Conference in Jan'
-
Boston Scientific (BSX) PT Raised to $110 at Truist Securities on Upside Potential
-
RBC's Best Picks For 2025 in Medical Supplies & Devices: 'Oasis of Opportunity Awaits as MedTech Momentum Continues'
-
Boston Scientific (BSX) Pacemakers May Need Early Replacement - FDA
-
TD Cowen on Boston Scientific (BSX): 'Next-Level Growth Plan Ready to Deliver Another Big Year'; Best Idea for 2025
-
RBC comments on medical devices sector ahead of EW's Investor Day
-
Is Trump 2.0 good or bad for healthcare stocks?
-
Needham Reiterates Hold Rating on Boston Scientific (BSX)
-
Boston Scientific (BSX) to Acquire Intera Oncology
-
TD Cowen Reiterates Buy Rating on Boston Scientific (BSX)
-
Boston Scientific (BSX) Closes Acquisition of Axonics (AXNX)
-
TD Cowen Reiterates Buy Rating on Boston Scientific (BSX)
-
Boston Scientific (BSX) to Acquire Cortex
-
Boston Scientific (BSX): ACURATE neo2 Aortic Valve System Data Presented at Late-Breaking Clinical Trial Session at TCT 2024
-
Medtronic (MDT) Gains, Boston Scientific (BSX) Declines
-
TD Cowen Reiterates Buy Rating on Boston Scientific (BSX)
-
Boston Scientific (BSX) PT Raised to $98 at RBC Capital
-
CL King Reiterates Buy Rating on Boston Scientific (BSX)
-
Buy the dip in this MedTech stock says Citi
-
Boston Scientific (BSX) Tops Q3 EPS by 4c; offers guidance
-
Boston Scientific (BSX) call put ratio 1.7 calls to 1 put into quarter results
-
Boston Scientific (BSX) call put ratio 2 calls to 1 put into quarter results
-
Boston Scientific (BSX) PT Raised to $100 at TD Cowen
-
Piper Sandler Reiterates Overweight Rating on Boston Scientific (BSX)
-
Boston Scientific (BSX) PT Raised to $98 at Canaccord Genuity
-
Boston Scientific (BSX) Launches Next Generation of Cardiac Mapping for the FARAPULSE⢠Pulsed Field Ablation System
-
Boston Scientific (BSX) PT Raised to $100 at Stifel
-
Boston Scientific (BSX) PT Raised to $100 at Baird
-
TD Cowen Reiterates Buy Rating on Boston Scientific (BSX)
-
TD Cowen Reiterates Buy Rating on Boston Scientific (BSX)
-
Boston Scientific (BSX) Receives Japanese Regulatory Approval for the FARAPULSE Pulsed Field Ablation System
-
BofA Securities Reiterates Buy Rating on Boston Scientific (BSX)
-
Piper Sandler Reiterates Overweight Rating on Boston Scientific (BSX)
-
Boston Scientific (BSX) Closes Acquisition of Silk Road Medical
-
Boston Scientific (BSX) Receives FDA Approval for Expanded Indication of INGEVITY+ Pacing Leads
-
Boston Scientific (BSX) Appoints David Habiger to its Board
-
Boston Scientific (BSX) PT Raised to $91 at Baird
-
Boston Scientific (BSX) PT Raised to $88 at Canaccord Genuity
-
Boston Scientific (BSX) PT Raised to $78 at Deutsche Bank
-
Boston Scientific (BSX) PT Raised to $90 at Jefferies
-
BTIG Reiterates Buy Rating on Boston Scientific (BSX)

